Verus Capital Partners LLC Takes Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Verus Capital Partners LLC bought a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 11,875 shares of the company’s stock, valued at approximately $55,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Versor Investments LP purchased a new position in GoodRx during the fourth quarter worth approximately $54,000. EP Wealth Advisors LLC purchased a new position in GoodRx during the third quarter worth approximately $73,000. Sanctuary Advisors LLC purchased a new position in GoodRx during the third quarter worth approximately $85,000. Sugar Maple Asset Management LLC purchased a new position in GoodRx during the fourth quarter worth approximately $122,000. Finally, Olympiad Research LP purchased a new position in GoodRx during the fourth quarter worth approximately $147,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on GDRX. Mizuho began coverage on GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective on the stock. Citigroup reduced their price objective on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. Barclays reduced their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Wells Fargo & Company cut their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research note on Friday. Finally, KeyCorp cut their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, GoodRx presently has a consensus rating of “Moderate Buy” and an average price target of $8.18.

GoodRx Stock Performance

Shares of NASDAQ GDRX opened at $4.98 on Friday. GoodRx Holdings, Inc. has a twelve month low of $4.09 and a twelve month high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a fifty day simple moving average of $4.71 and a 200-day simple moving average of $5.74. The stock has a market capitalization of $1.90 billion, a PE ratio of -166.00, a PEG ratio of 2.46 and a beta of 1.28.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.